Chemotherapy regimens for patients with pancreatic cancer combined with liver metastases, including gemcitabine combined with albumin combined with paclitaxel or gemcitabine combined with tegretol. Pancreatic cancer is a gastrointestinal malignant tumor with insidious onset, rapid progression, and extremely poor treatment outcome and prognosis. For patients with pancreatic cancer combined with liver metastasis, aggressive chemotherapy can help relieve symptoms, improve quality of life and prolong survival. According to the patients’ physical status, the preferred combination treatment program, such as FOLFIRINOX, gemcitabine combined with albumin-binding paclitaxel or gemcitabine combined with Tegio, etc., and those with poor physical status can choose gemcitabine or Tegio single-agent program. Gemcitabine combined with molecular targeted therapy is also a feasible choice. For pancreatic cancer patients who have progressed after first-line chemotherapy, non-overlapping drugs can be selected for second-line chemotherapy based on the drugs already used, physical status, comorbidities and adverse effects. Second-line chemotherapy is more effective than supportive therapy alone. For patients with good physical status, second-line chemotherapy includes nanoliposomal irinotecan combined with fluorouracil and calcium formyltetrahydrofolate, or fluorouracil combined with calcium formyltetrahydrofolate and oxaliplatin, etc.; for patients with poor physical status, they can choose gemcitabine or teguiline monotherapy. If pancreatic cancer is suspected or diagnosed, it is recommended to go to regular hospitals to evaluate the condition, follow the doctor’s instructions to cooperate with the treatment, and choose the appropriate program according to the situation to avoid delaying the condition. Please strictly follow the doctor’s instructions for drug treatment and do not use drugs on your own.